-

Foresight Diagnostics to Present at 43rd Annual J.P. Morgan Healthcare Conference

BOULDER, Colo.--(BUSINESS WIRE)--Foresight Diagnostics, Inc. (“Foresight”) a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, today announced that CEO, Jake Chabon, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30am Pacific Time.

Foresight Diagnostics will be hosting meetings at the LifeSci Corporate Access Event from January 13-15, 2025, and will also be available for additional meetings on January 16. To schedule a meeting with the Company, please contact InvestorRelations@foresight-dx.com.

About Foresight Diagnostics

Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. Its liquid biopsy platform, Foresight CLARITY™, is a novel assay that measures minimal residual disease (MRD) with reported detection limits in parts per million. The improved sensitivity of Foresight CLARITY has the potential to provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumor and hematologic malignancies.

For more information, please visit foresight-dx.com and follow us on X, BlueSky, and LinkedIn. Foresight CLARITY™ IUO is an investigational device. Limited by United States Law to investigational use.

Contacts

Media inquiries:
Press@foresight-dx.com

Industry:

Foresight Diagnostics, Inc.

Release Summary
Foresight Diagnostics, Inc. (“Foresight”) announced that CEO Jake Chabon will present at the 43rd Annual J.P. Morgan Healthcare Conference on Jan. 15.
Release Versions
English

Contacts

Media inquiries:
Press@foresight-dx.com

More News From Foresight Diagnostics, Inc.

Foresight Diagnostics Announces Launch of SHORTEN-ctDNA Trial to Evaluate Personalized Treatment Duration in DLBCL Lymphoma Patients

BOULDER, Colo.--(BUSINESS WIRE)--Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the launch of SHORTEN-ctDNA, a clinical trial at Columbia University.1 The study aims to evaluate the ability to utilize Foresight CLARITY™ MRD detection to enable real-time treatment optimization for patients with diffuse large B-cell lymphoma (DLBCL). Currently the standard treatment for newly diagnosed DLBCL requires six cycles of combinatio...

Foresight Diagnostics and Leading Global Cancer Center to Present New Data on Foresight CLARITY™ Ultra-Sensitive MRD Detection in Early-Stage Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

BOULDER, Colo.--(BUSINESS WIRE)--Foresight Diagnostics (Foresight) today announced new data from its ultra-sensitive Foresight CLARITY™ minimal residual disease (MRD) platform in early-stage breast cancer that will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) this month. Foresight and Memorial Sloan Kettering (MSK) will present an analysis of 470 samples from 81 early-stage breast cancer patients demonstrating that ctDNA clearance following various perioperative treatmen...

Foresight Diagnostics to Present New Data on Foresight CLARITY™ Ultra-Sensitive MRD Detection Across Multiple Studies at the 66th American Society of Hematology Annual Meeting

BOULDER, Colo.--(BUSINESS WIRE)--Foresight Diagnostics announced the presentation of multiple studies at the upcoming 66th American Society of Hematology Annual Meeting....
Back to Newsroom